Andreas Weiler brings over 25 years of experience in the CDMO and biopharmaceutical manufacturing industry, specializing in areas such as ADCs, bioconjugates, exosomes, recombinant proteins, HPAPIs, and cell and gene therapies. Throughout his career, he has accompanied more than 200 clinical projects, including the commercial launch of several products. Andreas began his career at Sigma Aldrich (SAFC), now Merck Millipore, and later moved to Lonza, where he led their Emerging Technology business. During his tenure at Lonza, he oversaw the construction of the world’s largest cell and gene therapy facility in Houston, spanning almost 300,000 square feet. He also played a key role in expanding Lonza’s cell and gene therapy footprint by acquiring Pharma Cell in Europe and forming a strategic collaboration with Nikon in Japan. Additionally, he facilitated the acquisition of the automation technology "CocoonTM," which is crucial for success in the cell therapy space.

​

In his leadership role at Lonza, Andreas signed numerous strategic customer agreements, positioning the company as the number one CDMO for late-phase cell and gene therapy projects. Over the past three years, Andreas has worked for Novartis, leading a global team to identify new strategic external partnerships and build a reliable global network of strategic manufacturing partners. His team successfully redesigned and expanded the external autologous manufacturing footprint for KymriahTM from one to four external commercial autologous manufacturing sites in Germany, Japan, Australia, and China. Furthermore, he implemented a switch to a suspension process for viral vector manufacturing for KymriahTM, significantly reducing costs by a factor of 10-20. Andreas's extensive expertise and strategic vision have made substantial contributions to the advancement of biopharmaceutical manufacturing and development.